Start Global Navigation

  1. Home
  2. About RCAST
  3. Research
  4. Industry-Academia-Government Collaboration
  5. International Collaboration
Research

Start Main Contents

Researcher's Profile

Project Professor

Hirofumi DOI

System Biology and Medicine

Biography

1983.03
PhD, School of Science, Kyoto University
Line
1985.02
Researcher, IIAS, Fujitsu Ltd.
Line
1995.10
Director, ERATO Doi Project, JST
Line
2001.10
Visiting Professor, Nara Institute of Science and Technology
Line
2010.07
Professor, RCAST, The University of Tokyo(UTokyo) (~2018.03)

Research Interests

In 1997 the FDA sanctioned Rituxan as the first monoclonal antibody drug for cancer therapy, and after that many antibody drugs have been marketed. Rituxan is a chimeric antibody of mouse Fab and human Fc regions. Herceptin approved in 1998 is also a monoclonal antibody drug for breast cancer, but a humanized antibody. Genome analysis projects of mouse and human were going on in 1998, and completed in 2002 and 2003, respectively. This research group has been trying to humanize mouse monoclonal antibodies as well as extraneous proteins from the omics information based on human and mouse genomes. As an example of extraneous proteins, low immunogenic strepavidin (SA) that strongly binds biotin will be applicable as a medicine. The low immunogenic SA fused with single chain Fv antibody will enable pretargeted radioimmunotherapy.



Start Site Information

page top

Copyright (c) RCAST, The University of Tokyo